Research and Development Investment: Sanofi vs Dr. Reddy's Laboratories Limited

R&D Investment Trends: Sanofi vs Dr. Reddy's

__timestampDr. Reddy's Laboratories LimitedSanofi
Wednesday, January 1, 2014124020000004667000000
Thursday, January 1, 2015174490000005082000000
Friday, January 1, 2016178340000005232000000
Sunday, January 1, 2017195510000005567000000
Monday, January 1, 2018182650000006350000000
Tuesday, January 1, 2019156070000006018000000
Wednesday, January 1, 2020154100000005529000000
Friday, January 1, 2021165410000005692000000
Saturday, January 1, 2022174820000006706000000
Sunday, January 1, 2023193810000006728000000
Monday, January 1, 2024228730000007394000000
Loading chart...

Cracking the code

A Decade of R&D Investment: Sanofi vs Dr. Reddy's Laboratories

In the competitive landscape of pharmaceuticals, research and development (R&D) investment is a key driver of innovation and growth. Over the past decade, Dr. Reddy's Laboratories Limited has consistently outpaced Sanofi in R&D spending. From 2014 to 2023, Dr. Reddy's increased its R&D expenses by approximately 85%, peaking in 2024 with a remarkable 22.9 billion. In contrast, Sanofi's R&D investment grew by about 44% over the same period, reaching its highest in 2023 with 6.7 billion. This trend highlights Dr. Reddy's commitment to innovation, as it invests significantly more in R&D compared to Sanofi. However, the data for 2024 is incomplete for Sanofi, leaving room for speculation on its future strategy. As the pharmaceutical industry evolves, these investments will likely shape the next wave of medical breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025